Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3151 - High-Dose versus Low-Dose Cisplatin With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck (SCC): An Analysis of Veteran’s Health Registry Data


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Surgical Oncology;  Radiation Oncology;  Head and Neck Cancers


Joshua Bauml


Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374


J. Bauml1, R. Vinnakota2, Y.A. Park3, S.E. Bates2, T. Fojo2, C. Aggarwal4, S. Lunate3, N. Damjanov1, R. Mamtani4, C.J. Langer4, R.B. Cohen4, K. Sigel5

Author affiliations

  • 1 Hematology/oncology, Corporal Michael J Crescenz VA Medical Center, 19104 - Philadelphia/US
  • 2 Hematology/oncology, Columbia University Medical Center, 10032 - New York/US
  • 3 Hematology/oncology, James J Peters VA Medical Center, 10468 - New York/US
  • 4 Hematology/oncology, Perelman School of Medicine at the University of Pennsylvania, 19104 - Philadelphia/US
  • 5 Infectious Diseases, James J Peters VA Medical Center, 10468 - New York/US


Abstract 3151


Radiotherapy (RT) with concurrent high-dose cisplatin (HDC) improves outcomes for patients (pts) with SCC. Weekly low-dose cisplatin (LDC) is a widely used alternative approach. The comparative effectiveness and safety of these approaches is unknown. We compared the outcomes of pts treated with HDC and LDC within the Veteran’s Administration Corporate Data Warehouse (CDW).


We identified stage III-IVb SCC patients treated non-surgically with RT and HDC or LDC from 2002 to 2014 in the CDW. Pts were grouped by the dose of their first cycle (HDC vs LDC; intent-to-treat). Variables including cancer site, stage, smoking/alcohol use, and comorbidities were used to generate propensity scores (PS) for the use of HDC. We compared overall survival (OS) by treatment group using Cox regression models, adjusting for PS. We also determined the risk of toxicities using PS-adjusted logistic regression models.


A total of 2,820 pts were included in the analysis: 69.7% received HDC (mean initial dose 96 mg/m2). The mean initial dose of LDC was 30 mg/m2. HDC pts were younger (p 


While HDC does not improve OS over LDC for the overall cohort of patients with SCC receiving RT with definitive intent, it is associated with a survival benefit for patients with OP. HDC is associated with more adverse events.

Clinical trial identification


Legal entity responsible for the study

Keith Sigel




J. Bauml: Research Support: Merck, Bayer, Novartis, Carevive Systems Consulting: Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Celgene, Genentech, Merck, Guardant Health. C. Aggarwal: Roche, Bristol-Myers Squibb, Eli Lilly: Ad boards Takeda, Macrogenics, Roche: Research support to institution. C.J. Langer: Research: Pfizer, Lilly, Genentech, OSI; GSK; Clovis; Merck; Nektar; Advantagene; Inovio; Takeda; AbbVie Advisor: Bristol-Myers Squibb, ImClone, Pfizer, Lilly; AstraZeneca; Merck; Novartis; Genentech; Bayer; Celgene; Abbott; Biodesix; Clariant; Caris; ARIAD; Boehringer Ingelheim; Synta; Clovis; Amgen; Synta; Peregrine; Incyte. R.B. Cohen: Takeda scientific ad board Zymeworks, Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.